The Beauty Health Company (SKIN)
NASDAQ: SKIN · IEX Real-Time Price · USD
3.060
-0.090 (-2.86%)
At close: Apr 25, 2024, 4:00 PM
3.070
+0.010 (0.33%)
After-hours: Apr 25, 2024, 7:31 PM EDT

The Beauty Health Company Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Revenue
397.99365.88260.09119.09166.62112.31
Revenue Growth (YoY)
8.78%40.68%118.39%-28.53%48.36%-
Cost of Revenue
242.88117.181.5551.8960.1139.34
Gross Profit
155.11248.78178.5467.2106.5172.98
Selling, General & Admin
275.93266.18210.2780.9788.4460.51
Research & Development
10.18.448.23.414.612.4
Operating Expenses
286.03274.62218.4784.3893.0562.92
Operating Income
-130.92-25.84-39.93-17.1813.4610.06
Interest Expense / Income
13.6513.3911.7821.2817.0910.05
Other Expense / Income
-42.68-84.57328.930.03-0.70
Pretax Income
-101.8945.34-380.64-38.48-2.940.01
Income Tax
-1.771.12-1.88-9.31-1.30.33
Net Income
-100.1244.22-378.76-29.18-1.64-0.32
Preferred Dividends
0000090.61
Net Income Common
-100.1244.22-378.76-29.18-1.64-90.93
Shares Outstanding (Basic)
132148102343249
Shares Outstanding (Diluted)
132149102343249
Shares Change
-11.33%45.43%197.77%6.71%-34.62%-
EPS (Basic)
-0.760.30-3.71-0.85-0.05-1849.99
EPS (Diluted)
-0.76-0.23-3.71-0.85-0.05-1849.99
Free Cash Flow
8.7-123.99-43.98-16.25-8.69-8.78
Free Cash Flow Per Share
0.07-0.84-0.43-0.47-0.27-0.18
Gross Margin
38.97%68.00%68.65%56.43%63.92%64.98%
Operating Margin
-32.89%-7.06%-15.35%-14.43%8.08%8.96%
Profit Margin
-25.16%12.09%-145.63%-24.50%-0.98%-80.96%
Free Cash Flow Margin
2.19%-33.89%-16.91%-13.65%-5.22%-7.82%
Effective Tax Rate
-2.46%---3270.00%
EBITDA
-53.5781.6-350.93-2.6828.121.56
EBITDA Margin
-13.46%22.30%-134.93%-2.25%16.87%19.19%
Depreciation & Amortization
34.6822.8717.9314.5313.9411.5
EBIT
-88.2458.73-368.86-17.2114.1610.06
EBIT Margin
-22.17%16.05%-141.82%-14.45%8.50%8.96%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).